Your prediction
Sonnet Biotherapeutics Holdings Inc. Stock
For the coming years our community has positive and negative things to say abot the Sonnet Biotherapeutics Holdings Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Sonnet Biotherapeutics Holdings Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sonnet Biotherapeutics Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc. | - | - | - | - | - | - | - |
| Skylark Co Ltd | 0.000% | -6.630% | -4.520% | -5.056% | -5.056% | 43.220% | 31.008% |
| J D Wetherspoon plc | -0.710% | 6.061% | -7.895% | 6.061% | -15.152% | -17.501% | -57.524% |
| SSP Group plc | 13.000% | 4.615% | 3.553% | 38.776% | -6.422% | -24.444% | -42.503% |
Comments
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its price target lowered by analysts at Chardan Capital from $30.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for SONN provided by MarketBeat